Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Hoda Sadek"'
Publikováno v:
Dental and Medical Problems. 61
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad8fc54bb2a7b0e511bb4ac41f185c2f
https://doi.org/10.17219/dmp/162573
https://doi.org/10.17219/dmp/162573
Autor:
Ahmed El-banna, Hoda Sadek
Publikováno v:
Journal of Prosthodontics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a38095d6726a0f86983fe4d457fcb2b
https://doi.org/10.1111/jopr.13662
https://doi.org/10.1111/jopr.13662
Autor:
Somaia Mohammed Mousa, Hoda Sadek, Amany A. Abou-Elalla, Gehad Atef, Ilham Youssry, Nihal Salah Ibrahim
Publikováno v:
Fetal and pediatric pathology. 36(3)
Development of inhibitors against Factor VIII (FVIII) in hemophilia A patients is a serious complication of therapy. Many cytokines, including interleukin-10 (IL10), may affect inhibitor development; however, literature data are not sufficient to pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2a43580667e8fdb41986c8273c1e7a3
https://pubmed.ncbi.nlm.nih.gov/28574805
https://pubmed.ncbi.nlm.nih.gov/28574805
Autor:
Emad El-Din A. Bayoumi, Hoda Sadek, Bothaina S. Madkour, Salwa M. Toima, Rabab F. Yaseen, Iman A. Shaheen, Abeya F. Saleh
Publikováno v:
Arab Journal of Gastroenterology. 11:124-129
Background and study aims Bleeding and thrombotic complications are common problems in patients with chronic liver disease (CLD). The aim of the present study was to evaluate the level of soluble P (sP)-selectin and P-selectin glycoprotein ligand-1 (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f754cd3e48f25f7e60d8908562480e85
https://doi.org/10.1016/j.ajg.2010.07.005
https://doi.org/10.1016/j.ajg.2010.07.005
Autor:
Iman A. Shaheen, Mervat Mamdouh Korshied, Hoda Sadek, Azza Sobieh Mohamed, Wafaa Hassan El-Metnawey
Publikováno v:
Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 59(8)
Background Accurate assessment of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) patients after initial chemotherapy is essential to evaluate the efficacy of therapeutic regimens. Wilms tumor 1 ( WT1) is a pan-leukemic marker us
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0782dbba2f24680f6d95cac003825d45
https://pubmed.ncbi.nlm.nih.gov/21804407
https://pubmed.ncbi.nlm.nih.gov/21804407